Inato and RealTime eClinical Solutions have announced a partnership aimed at improving trial site selection and subject enrolment.
This collaboration merges RealTime-Devana’s TrialAlign site performance data with Inato’s patient access information, offering pharmaceutical sponsors and contract research organisations (CROs) improved insights for identifying high-performing, enrolment-ready sites.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It enhances access to over 50 networks, comprising more than 2,000 sites that are currently utilising RealTime-Devana systems. These will be integrated with Inato’s existing network of over 5,500 sites.
The integration allows sponsors to view TrialAlign’s up-to-date site metrics data within the Inato platform, thereby expanding the pool of qualified sites available for clinical trials.
RealTime-Devana’s business intelligence platform assists site networks in improving trial operations through the automation of study start-up processes, pipeline management, and extensive reporting and dashboard systems.
As a result of this partnership, participating sites receive priority access to Inato’s AI-driven patient pre-screening solution, which can decrease chart review times by as much as 90%, and will be able to showcase their patient access capabilities during feasibility evaluations.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataInato co-founder and CEO Kourosh Davarpanah said: “We built Inato to bring trials to all sites and patients. This partnership brings us a big step closer.
“By joining forces with RealTime’s TrialAlign, we’ll enable site networks to showcase proven patient access, activation speed, and enrolment performance to top sponsors, helping them secure the right trials for their patients.”
RealTime-Devana founder and president Barry Lake said: “Unbiased site performance data plus patient access data is the holy grail in terms of site selection and trial feasibility. Through this partnership with Inato, this holy grail can be delivered to sponsors and CROs.
“Together, we help sites put their best foot forward and enable sponsors to confidently partner with sites based on proven performance, engagement, and readiness.”
